Search our Database of Scientific Publications and Authors

I’m looking for a
    No evidence of persistent parvovirus B19 viremia among Iranian patients with HIV after a 1-year follow-up.
    Arch Virol 2016 May 10;161(5):1183-7. Epub 2016 Feb 10.
    Clinical Research Department, Pasteur Institute of Iran, No 69, Pasteur Ave., Tehran, 13164, Iran.
    Recent studies have demonstrated that, in common with other latent viruses, parvovirus B19 infection can be controlled by the host immune response but may persist in some places such as the bone marrow. Persistent B19 infection has been found in both immunocompetent and immunocompromised individuals, such as patients infected with human immunodeficiency virus (HIV). However, there is limited data regarding long-term B19 viremia in HIV patients. In this study, we investigated virological and hematological findings, and also the clinical outcome, of seven cases of HIV/B19 coinfection (confirmed by PCR) after one year. These cases were provided from a previous study on patients with HIV infection that found B19 DNA in 13 cases. Seven of these 13 patients were available after 1 year, and we retested them for B19 viremia and B19-specific antibodies. B19 IgG was tested by ELISA, and B19 DNA was assessed by nested PCR. Anemia was not observed in these cases. All subjects had cleared viremia, but B19 IgG seroconversion occurred in two cases. No significant changes in CD4 and hemoglobin occurred. The results of this study indicate that B19 infection in HIV patients is a subtle infection and that B19 viremia is not a long-term event.

    Similar Publications

    Frequency and genotype of human parvovirus B19 among Iranian patients infected with HIV.
    J Med Virol 2015 Jul 13;87(7):1124-9. Epub 2015 Mar 13.
    Department of Virology, Pasteur Institute of Iran, Tehran, Iran.
    The human parvovirus B19 (B19) usually causes a subclinical infection in immunocompetent individuals. Whereas immunocompromised individuals such as patients infected with HIV are at risk of persistent anemia due to B19 infection. Only few studies have been carried out on distribution and molecular epidemiology of B19 in Iran. Read More
    Infection due to parvovirus B19 in patients infected with human immunodeficiency virus.
    Clin Infect Dis 1995 Jan;20(1):170-3
    Department of Medicine, Hospital of the University of Pennsylvania.
    Parvovirus B19 has been described as a cause of chronic anemia in immunosuppressed patients, including those infected with human immunodeficiency virus (HIV). In this study serological assays and the polymerase chain reaction (PCR) were used to establish the prevalence of both prior and active infection due to parvovirus B19 among a general population of 105 HIV-infected individuals (cohort I) and among 22 HIV-infected patients with anemia (cohort II). Eight individuals in cohort I (7. Read More
    Parvovirus B19-related anemia in HIV-infected patients.
    AIDS Patient Care STDS 2000 Jan;14(1):7-11
    Division of Hematology, Cook County Hospital and Rush Medical College, Chicago, Illinois 60612, USA.
    Persistent infection with parvovirus B19 (B19) is an important treatable cause of anemia in HIV-infected patients. B19 has a tropism for erythroid progenitors and causes pure red cell aplasia (PRCA). The failure to produce neutralizing antibodies to the virus following B19 infection in immunodeficient persons may result in persistent viremia and chronic PRCA (B19-PRCA). Read More